

# TRACTATENBLAD

VAN HET

KONINKRIJK DER NEDERLANDEN

---

---

JAARGANG 2023 Nr. 1

---

---

## A. TITEL

*Overeenkomst ter bestrijding van doping (met Bijlage);  
Straatsburg, 16 november 1989*

Voor een overzicht van de verdragsgegevens, zie verdragsnummer 003898 in de Verdragenbank.

## B. TEKST

De Commissie van Toezicht heeft op 2 november 2022, op grond van artikel 11, eerste lid, onder b, van de Overeenkomst, een wijziging van de Bijlage aangenomen. De Engelse tekst<sup>1)</sup> van de wijziging luidt als volgt:

**Anti-doping convention (ETS no. 135) – amendment to the appendix**

**(approved by the Monitoring Group by written procedure under Article 11.1.b of the Convention on 2 November 2022)**

**The 2023 Prohibited List**

**– World Anti-Doping Code**

**Date of entry into force: 1 January 2023**

*Introduction*

The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program.

The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 01 January 2023.

The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

Below are some terms used in this List of Prohibited Substances and Prohibited Methods.

*Prohibited In-Competition*

Subject to a different period having been approved by WADA for a given sport, the In-Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process.

*Prohibited at all times*

This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code.

---

<sup>1)</sup> De Franse tekst is niet opgenomen.

## *Specified and non-Specified*

As per Article 4.2.2 of the World Anti-Doping Code, "for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List. No Prohibited Method shall be a Specified Method unless it is specifically identified as a Specified Method on the Prohibited List". As per the comment to the article, "the Specified Substances and Methods identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance."

## *Substances of Abuse*

Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/"ecstasy"), tetrahydrocannabinol (THC).

## *SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES*

### *S0. NON-APPROVED SUBSTANCES*

All prohibited substances in this class are prohibited at all times (in- and out-of-competition). All prohibited substances in this class are Specified Substances

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

This class covers many different substances including but not limited to BPC-157.

### *S1. ANABOLIC AGENTS*

All prohibited substances in this class are prohibited at all times (in- and out-of-competition). All prohibited substances in this class are non-Specified Substances.

Anabolic agents are prohibited.

#### **1. ANABOLIC ANDROGENIC STEROIDS (AAS)**

When administered exogenously, including but not limited to:

- 1-Androstenediol (5 $\alpha$ -androst-1-ene-3 $\beta$ ,17 $\beta$ -diol)
- 1-Androstenedione (5 $\alpha$ -androst-1-ene-3,17-dione)
- 1-Androsterone (3 $\alpha$ -hydroxy-5 $\alpha$ -androst-1-ene-17-one)
- 1-Epiandrosterone (3 $\beta$ -hydroxy-5 $\alpha$ -androst-1-ene-17-one)
- 1-Testosterone (17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one)
- 4-Androstenediol (androst-4-ene-3 $\beta$ ,17 $\beta$ -diol);
- 4-Hydroxytestosterone (4,17 $\beta$ -dihydroxyandrost-4-en-3-one)
- 5-Androstenedione (androst-5-ene-3,17-dione)
- 7 $\alpha$ -hydroxy-DHEA
- 7 $\beta$ -hydroxy-DHEA
- 7-Keto-DHEA
- 17-methylepithiostanol (epistane)
- 19-Norandrostenediol (estr-4-ene-3,17-diol)
- 19-Norandrostenedione (estr-4-ene-3,17-dione)
- Androst-4-ene-3,11,17-trione (11-ketoandrostenedione, adrenosterone)
- Androstanolone (5 $\alpha$ -dihydrotestosterone, 17 $\beta$ -hydroxy-5 $\alpha$ -androstan-3-one)
- Androstenediol (androst-5-ene-3 $\beta$ ,17 $\beta$ -diol)
- Androstenedione (androst-4-ene-3,17-dione)
- Bolasterone
- Boldenone
- Boldione (androsta-1,4-diene-3,17-dione)
- Calusterone
- Clostebol
- Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 $\alpha$ -ol)
- Dehydrochlormethyltestosterone (4-chloro-17 $\beta$ -hydroxy-17 $\alpha$ -methylandrosta-1,4-dien-3-one)
- Desoxymethyltestosterone (17 $\alpha$ -methyl-5 $\alpha$ -androst-2-en-17 $\beta$ -ol and 17 $\alpha$ -methyl-5 $\alpha$ -androst-3-en-17 $\beta$ -ol)
- Drostanolone
- Epiandrosterone (3 $\beta$ -hydroxy-5 $\alpha$ -androstan-17-one)

Epi-dihydrotestosterone (17 $\beta$ -hydroxy-5 $\beta$ -androstan-3-one)  
 Epitestosterone  
 Ethylestrenol (19-norpregna-4-en-17 $\alpha$ -ol) Fluoxymesterone  
 Formebolone  
 Furazabol (17 $\alpha$ -methyl [1,2,5]oxadiazolo[3',4':2,3]-5 $\alpha$ -androstan-17 $\beta$ -ol)  
 Gestrinone  
 Mestanolone  
 Mesterolone  
 Metandienone (17 $\beta$ -hydroxy-17 $\alpha$ -methylandrosta-1,4-dien-3-one)  
 Metenolone  
 Methandriol  
 Methasterone (17 $\beta$ -hydroxy-2 $\alpha$ ,17 $\alpha$ -dimethyl-5 $\alpha$ -androstan-3-one)  
 Methyl-1-testosterone (17 $\beta$ -hydroxy-17 $\alpha$ -methyl-5 $\alpha$ -androst-1-en-3-one)  
 Methylclostebol  
 Methyldienolone (17 $\beta$ -hydroxy-17 $\alpha$ -methylestra-4,9-dien-3-one)  
 Methylnortestosterone (17 $\beta$ -hydroxy-17 $\alpha$ -methylestr-4-en-3-one)  
 Methyltestosterone  
 Metribolone (methyltrienolone, 17 $\beta$ -hydroxy-17 $\alpha$ -methylestra-4,9,11-trien-3-one)  
 Mibolerone  
 Nandrolone (19-nortestosterone)  
 Norboletone  
 Norclostebol (4-chloro-17 $\beta$ -ol-estr-4-en-3-one)  
 Norethandrolone  
 Oxabolone  
 Oxandrolone  
 Oxymesterone  
 Oxymetholone  
 Prasterone (dehydroepiandrosterone, DHEA, 3 $\beta$ -hydroxyandrost-5-en-17-one)  
 Prostanazol (17 $\beta$ -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 $\alpha$ - androstane)  
 Quinbolone  
 Stanozolol  
 Stenbolone  
 Testosterone  
 Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17 $\alpha$ -pregna-4,9,11-trien-3-one)  
 Tibolone  
 Trenbolone (17 $\beta$ -hydroxyestr-4,9,11-trien-3-one)  
 and other substances with a similar chemical structure or similar biological effect(s).

## 2. **OTHER ANABOLIC AGENTS**

Including, but not limited to:

Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol.

## *S2. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS*

All prohibited substances in this class are prohibited at all times (in- and out-of-competition). All prohibited substances in this class are non-Specified Substances

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

### 1. **ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS**

Including, but not limited to:

1.1 Erythropoietin receptor agonists, e.g. darbepoietin (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO 530, peginesatide).

1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon.

1.3 GATA inhibitors, e.g. K-11706.

1.4 Transforming growth factor beta (TGF- $\beta$ ) signalling inhibitors, e.g. luspatercept; sotatercept.

1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO).

### 2. **PEPTIDE HORMONES AND THEIR RELEASING FACTORS**

2.1 Chorionic gonadotrophin (CG) and luteinizing hormone (LH) and their releasing factors in males, e.g. busarelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin.

2.2 Corticotrophins and their releasing factors, e.g. corticorelin.

2.3 Growth hormone (GH), its analogues and fragments including, but not limited to: growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogen growth hormone fragments, e.g. AOD-9604 and hGH 176-191.

Growth hormone releasing factors, including, but not limited to:

- 2.4 growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)  
growth hormone secretagogues (GHS) and their mimetics [e.g. lenomorelin (ghrelin), anamorelin, ipamorelin, macimorelin and tabimorelin];  
GH-releasing peptides (GHRPs) [e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin)].

### 3. **GROWTH FACTORS AND GROWTH FACTOR MODULATORS**

Including, but not limited to:

- Fibroblast growth factors (FGFs)
- Hepatocyte growth factor (HGF)
- Insulin-like growth factor 1 (IGF-1) and its analogues
- Mechano growth factors (MGFs)
- Platelet-derived growth factor (PDGF)
- Thymosin- $\beta$ 4 and its derivatives e.g. TB-500
- Vascular endothelial growth factor (VEGF)

and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

### *S3. BETA-2 AGONISTS*

All prohibited substances in this class are prohibited at all times (in- and out-of-competition). All prohibited substances in this class are Specified Substances

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to:

- Arformoterol
- Fenoterol
- Formoterol
- Higenamine
- Indacaterol
- Levosalbutamol
- Olodaterol
- Procaterol
- Reproterol
- Salbutamol
- Salmeterol
- Terbutaline
- Tretoquinol (trimetoquinol)
- Tulobuterol
- Vilanterol

### **EXCEPTIONS**

- Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose;
- Inhaled formoterol: maximum delivered dose 54 micrograms over 24 hours;
- Inhaled salmeterol: maximum 200 micrograms over 24 hours.
- Inhaled vilanterol: maximum 25 micrograms over 24 hours.

### **NOTE**

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.

### *S4. HORMONE AND METABOLIC MODULATORS*

All prohibited substances in this class are prohibited at all times (in- and out-of-competition).

Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances.

The following hormone and metabolic modulators are prohibited:

- 4.1 AROMATASE INHIBITORS  
Including, but not limited to:  
2-Androstenol (5 $\alpha$ -androst-2-en-17-ol)  
2-Androstenone (5 $\alpha$ -androst-2-en-17-one)  
3-Androstenol (5 $\alpha$ -androst-3-en-17-ol)  
3-Androstenone (5 $\alpha$ -androst-3-en-17-one)  
4-Androstene-3,6,17 trione (6-oxo)  
Aminoglutethimide  
Anastrozole  
Androsta-1,4,6-triene-3,17-dione (androstatrienedione)  
Androsta-3,5-diene-7,17-dione (arimistane)  
Exemestane  
Formestane  
Letrozole  
Testolactone
- 4.2 ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)]  
Including, but not limited to:  
Bazedoxifene  
Clomifene  
Cyclofenil  
Fulvestrant  
Ospemifene  
Raloxifene  
Tamoxifen  
Toremifene
- 4.3 AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION  
Including, but not limited, to:  
Activin A-neutralising antibodies;  
Activin receptor IIB competitors such as:  
– Decoy activin receptors (e.g. ACE-031);  
Anti-activin receptor IIB antibodies (e.g. bimagrumb);  
Myostatin inhibitors such as:  
– Agents reducing or ablating myostatin expression  
– Myostatin-binding proteins (e.g. follistatin, myostatin propeptide)  
– Myostatin- or precursor-neutralising antibodies (e.g. apitegromab, domagrozumab, landogrozumab, stamulumab)
- 4.4 METABOLIC MODULATORS  
4.1.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and peroxisome proliferator-activated receptor delta (PPAR $\delta$ ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516)  
4.1.2 Insulins and insulin-mimetics  
4.1.3 Meldonium  
4.1.4 Trimetazidine

## 5. DIURETICS AND MASKING AGENTS

All prohibited substances in this class are prohibited at all times (in- and out-of-competition). All prohibited substances in this class are Specified Substances

All diuretics and masking agents, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

Including, but not limited to:

- Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol.
- Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide; and hydrochlorothiazide; torasemide; triamterene and vaptans, e.g. tolvaptan

and other substances with a similar chemical structure or similar biological effect(s).

### EXCEPTIONS

- Drospirenone; pamabrom; and topical ophtalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide).
- Local administration of felypressin in dental anaesthesia.

### NOTE

The detection in an Athlete's Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent.

### *PROHIBITED METHODS*

All prohibited methods are prohibited at all times (in- and out-of-competition).  
All prohibited methods are non-Specified except methods in M2.2. which are Specified Methods.

#### *M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS*

The following are prohibited:

1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.
3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

#### *M2. CHEMICAL AND PHYSICAL MANIPULATION*

The following are prohibited:

1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control.  
Including, but not limited to:  
Sample substitution and/or adulteration, e.g. addition of proteases to Samples.
2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.

#### *M3. GENE AND CELL DOPING*

The following, with the potential to enhance sport performance, are prohibited:

1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies.
2. The use of normal or genetically modified cells.

### *SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION*

#### *S6. STIMULANTS*

All prohibited substances in this class are prohibited in-competition.  
All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances.

Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA/"ecstasy")

All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include:

##### **A: NON-SPECIFIED STIMULANTS**

Adrafinil  
Amfepramone  
Amfetamine  
Amfetaminil  
Amiphenazole  
Benfluorex  
Benzylpiperazine  
Bromantan  
Clobenzorex  
Cocaine  
Cropropamide  
Crotetamide

Fencamine  
Fenetylline  
Fenfluramine  
Fenproporex  
Fonturacetam [4-phenylpiracetam (carphedon)]  
Furfenorex  
Lisdexamfetamine  
Mefenorex  
Mephentermine  
Mesocarb  
Metamfetamine(*d*-)  
p-methylamphetamine  
Modafinil  
Norfenfluramine  
Phendimetrazine  
Phentermine  
Prenylamine  
Prolintane

A stimulant not expressly listed in this section is a Specified Substance.

**B: SPECIFIED STIMULANTS**

Including, but not limited to:

3-Methylhexan-2-amine (1,2- dimethylpentylamine)  
4-fluoromethylphenidate  
4-Methylhexan-2-amine (methylhexaneamine, 1,3-dimethylamylamine, 1,3 DMAA)  
4-Methylpentan-2-amine (1,3- dimethylbutylamine)  
5-Methylhexan-2-amine (1,4-dimethylpentylamine, 1,4- dimethylamylamine, 1,4-DMAA)  
Benzfetamine  
Cathine<sup>2)</sup>  
Cathinone and its analogues, e.g. mephedrone, methedrone, and  $\alpha$ - pyrrolidinovalerophenone  
Dimetamfetamine (dimethylamphetamine)  
Ephedrine<sup>3)</sup>  
Epinephrine<sup>4)</sup> (adrenaline)  
Etamivan  
Ethylphenidate  
Etilamfetamine  
Etilefrine  
Famprofazone  
Fenbutrazate  
Fencamfamin  
Heptaminol  
Hydrafinil (fluorenol)  
Hydroxyamfetamine (parahydroxyamphetamine)  
Isometheptene  
Levmetamfetamine  
Meclofenoxate  
Methylenedioxymethamphetamine  
Methylephedrine<sup>5)</sup>  
Methylnaphthidate [(( $\pm$ )-methyl-2- (naphthalen-2-yl)-2-(piperidin-2-yl)acetate]  
Methylphenidate  
Nikethamide  
Norfenefrine  
Octodrine (1,5-dimethylhexylamine)  
Octopamine  
Oxilofrine (methylsynephrine)  
Pemoline  
Pentetrazol  
Phenethylamine and its derivatives  
Phenmetrazine

<sup>2)</sup> Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre.

<sup>3)</sup> Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

<sup>4)</sup> Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co- administration with local anaesthetic agents.

<sup>5)</sup> Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

Phenpromethamine  
Propylhexedrine  
Pseudoephedrine<sup>6)</sup>  
Selegiline  
Sibutramine  
Solriamfetol  
Strychnine  
Tenamfetamine (methylenedioxyamphetamine)  
Tuaminoheptane  
and other substances with a similar chemical structure or similar biological effect(s).

#### **EXCEPTIONS**

- Clonidine;
- Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetrazyoline, xylometazoline) and those stimulants included in the 2023 Monitoring Program<sup>7)</sup>.

#### *S7. NARCOTICS*

All prohibited substances in this class are prohibited in-competition. All prohibited substances in this class are Specified Substances.

Substance of Abuse in this section: diamorphine (heroin)

The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

Buprenorphine  
Dextromoramide  
Diamorphine (heroin)  
Fentanyl and its derivatives  
Hydromorphone  
Methadone  
Morphine  
Nicomorphine  
Oxycodone  
Oxymorphone  
Pentazocine  
Pethidine

#### *S8. CANNABINOIDS*

All prohibited substances in this class are prohibited in-competition. All prohibited substances in this class are Specified Substances.

Substance of Abuse in this section: tetrahydrocannabinol (THC)

All natural and synthetic cannabinoids are prohibited, e.g.:

- In cannabis (hashish, marijuana) and cannabis products
- Natural and synthetic tetrahydrocannabinols (THCs)
- Synthetic cannabinoids that mimic the effects of THC

#### **EXCEPTIONS**

- Cannabidiol.

#### *S9. GLUCOCORTICOIDS*

All prohibited substances in this class are prohibited in-competition. All prohibited substances in this class are Specified Substances.

All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route.

<sup>6)</sup> Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre.

<sup>7)</sup> Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2023 Monitoring Program and are not considered Prohibited Substances.



Including but not limited to:

Beclometasone  
Betamethasone  
Budesonide  
Ciclesonide  
Cortisone  
Deflazacort  
Dexamethasone  
Flucortolone  
Flunisolide  
Fluticasone  
Hydrocortisone  
Methylprednisolone  
Mometasone  
Prednisolone  
Prednisone  
Triamcinolone acetonide

#### **NOTE**

Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer's licensed doses and therapeutic indications.

### *PROHIBITED IN PARTICULAR SPORTS*

#### *P1. BETA-BLOCKERS*

All prohibited substances in this class are Specified Substances

Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated (\*).

- Archery (WA)<sup>8)</sup>
- Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Darts (WDF)
- Golf (IGF)
- Mini-Golf (WMF)
- Shooting (ISSF, IPC)<sup>9)</sup>
- Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
- Underwater sports (CMAS)<sup>10)</sup> in all subdisciplines of freediving, spearfishing and target shooting.

Including but not limited to:

Acebutolol  
Alprenolol  
Atenolol  
Betaxolol;  
Bisoprolol  
Bunolol  
Carteolol  
Carvedilol  
Celiprolol  
Esmolol  
Labetalol  
Metipranolol;  
Metoprolol  
Nadolol  
Nebivolol  
Oxprenolol  
Pindolol  
Propranolol  
Sotalol

---

<sup>8)</sup> Also prohibited Out-of-Competition

<sup>9)</sup> Also prohibited Out-of-Competition

<sup>10)</sup> Also prohibited Out-of-Competition

---

#### G. INWERKINGTREDING

De wijziging van 2 november 2022 van de Bijlage bij de Overeenkomst is op 1 januari 2023 in werking getreden voor alle partijen bij de Overeenkomst, waaronder het Koninkrijk der Nederlanden.

Wat betreft het Koninkrijk der Nederlanden, geldt de wijziging van de Bijlage, evenals de Overeenkomst, voor Nederland (het Europese deel en het Caribische deel), Curaçao en Sint Maarten.

---

In overeenstemming met artikel 19, tweede lid, van de Rijkswet goedkeuring en bekendmaking verdragen heeft de Minister van Buitenlandse Zaken bepaald dat de wijziging van 2 november 2022 van de Bijlage bij de Overeenkomst zal zijn bekendgemaakt in Nederland (het Europese deel en het Caribische deel), Curaçao en Sint Maarten op de dag na de datum van uitgifte van dit Tractatenblad.

Uitgegeven de *twaaalfde* januari 2023.

*De Minister van Buitenlandse Zaken,*

W.B. HOEKSTRA